Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00127283 · ClinicalTrials.gov registry record · Phase 3
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 829
- Enrollment target
NCT00127283 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 829 participants.
The verdict
NCT00127283, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 829 participants
- Enrollment target
Study Summary
This trial is conducted in Asia, Europe, Middle East, North America, Oceania, and South America. The purpose of this study is to evaluate the treatment of Recombinant Factor VIIa (eptacog alfa (activated)) in patients with acute intracerebral bleeding. It is expected that more patients will recover without severe permanent disability after acute treatment with Recombinant Factor VIIa by reducing further intracerebral bleeding.
Interventions
- DRUG eptacog alfa (activated)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 829 participants |
| Start Date | 2005-05 |
| Est. Completion | 2007-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00127283
The ClinicalTrials.gov registry entry for NCT00127283 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 829 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which eptacog alfa (activated) is the first listed.
NCT00127283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00127283 about?
NCT00127283 is a clinical study titled "Recombinant Factor VIIa in Acute Intracerebral Haemorrhage". This trial is conducted in Asia, Europe, Middle East, North America, Oceania, and South America. The purpose of this study is to evaluate the treatment of Recombinant Factor VIIa (eptacog alfa (activated)) in patients with acute intracerebral bleeding. It is expected that more patients will recover...
What is the current status of trial NCT00127283?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 829 participants. The study started on 2005-05. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00127283?
The interventions under investigation include: eptacog alfa (activated) (DRUG).
Who is sponsoring clinical trial NCT00127283?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.